Received Jun 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | UNK | X014950 | — |
Email received on 29MAY2025 at 12:22 PM ET from Merck Employee titled: "Gardasil [Human Papillomavirus Quadrivalent Vaccine, Types 6, 11, 16, and 18, Recombinant] - HCP Request" containing a forwarded email from; No symptoms reported; This spontaneous report was received from a nurse practitioner and refers to a(n) female patient of unknown age. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient started therapy with Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL), lot #X014950, expiration date: 19-Dec-2025 (exact dose, route of administration and anatomical location were not provided) for an unknown indication. On an unknown date, the patient contacting to verify the authenticity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL) vaccine dose she received in another country. The vaccine was administered in a local clinic, but she did not see the outer packaging. She would like to confirm whether this batch (X014950) was officially distributed to country and whether it is part of a recognized public health or supported program. She would appreciate our confirmation and any additional information you could provide (suspected counterfeit product). No symptoms reported (no adverse event).